(Q33442594)

English

Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5690479

Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905). (English)

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5690479

phase I clinical trial

0 references

malignant pleural mesothelioma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David R Gandara

7

object named as

David R Gandara

1 reference

Europe PubMed Central

10 January 2018

PMC publication ID

Ignacio I Wistuba

3

object named as

Ignacio I Wistuba

1 reference

Europe PubMed Central

10 January 2018

PMC publication ID

Gregory P. Kalemkerian

5

object named as

Gregory P Kalemkerian

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5690479

author name string

Anne S Tsao

1

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5690479

James Moon

2

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5690479

Nicholas J Vogelzang

4

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5690479

Mary W Redman

6

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5690479

Karen Kelly

8

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5690479

publication date

6 June 2017

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5690479

Journal of Thoracic Oncology

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5690479

12

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5690479

8

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5690479

1299-1308

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5690479

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Mechanisms of TKI-induced diarrhea in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Mesothelioma cell proliferation through autocrine activation of PDGF-ββ receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Advances in the systemic therapy of malignant pleural mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

21 June 2018

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

31 October 2018

A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

31 October 2018

Serum PDGF-AB in pleural mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

31 October 2018

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

31 October 2018

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

31 October 2018

Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690479

31 October 2018

Characterization of platelet-derived growth factor and platelet-derived growth factor receptor expression in asbestos-induced rat mesothelioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28599887

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction

1 reference

https://pubmed.ncbi.nlm.nih.gov/28599887

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28599887

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/28599887

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.JTHO.2017.05.021

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5690479

release_zfl6fcsrufacnhw3md43li6aui

1 reference

https://api.fatcat.wiki/v0/release/zfl6fcsrufacnhw3md43li6aui

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5690479

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 January 2018

http://europepmc.org/abstract/PMC/5690479

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33442594&oldid=2104600651"